Impact of PD1 Blockade Added to Neoadjuvant Chemoradiotherapy on Rectal Cancer Surgery: Post-Hoc Analysis of the Randomized POLARSTAR Trial

Medicine, Oncology,
PD1 blockade   neoadjuvant chemoradiotherapy   rectal cancer   surgery   POLARSTAR trial  

Background Colorectal cancer is the third most common cancer type globally, with the greatest disease burden in East Asia. In China, 47% of newly diagnosed colorectal cancers are rectal cancers, of which 70% are radiologically staged as locally advanced (stage II/III) at diagnosis. For decades, neoadjuvant chemoradiotherapy (CRT) combined with tota...

Effect of Neoadjuvant Chemoradiotherapy with or without PD-1 Antibody Sintilimab in PMMR Locally Advanced Rectal Cancer: A Randomized Clinical Trial

Medicine, Gastroenterology, Oncology, Life Sciences, Immunology,
neoadjuvant chemoradiotherapy   PD-1 antibody   locally advanced rectal cancer   sintilimab   complete response rate  

The Role of Neoadjuvant Chemoradiotherapy Combined or Not Combined with PD-1 Antibody Sintilimab in pMMR Locally Advanced Rectal Cancer: Results of a Randomized Clinical Trial Background and Significance The management of rectal cancer and organ preservation has always been quite challenging, especially in cases of locally advanced rectal cancer (L...